Skip to main content

Table 2 Risk of SPC a by gender and first cancer site, France 1989–2004 (N = 289,967)

From: The effect of patient characteristics on second primary cancer risk in France

  Males Females
(N = 160, 807) (N = 129,160)
First cancer site O E PYR SIR EARb (95% CI) O E PYR SIR EARb (95% CI)
Lip 111 80.66 4,081 1.38* 74.3* (26.1-129.9) 13 8.44 806 1.54 56.6 (-18.9-171.2)
Tongue and lingual tonsil 329 90.84 6,794 3.62* 350.5* (299.6-405.8) 41 15.99 1,886 2.56* 132.6* (71.2-210.2)
Oral cavity 536 129.77 10,034 4.13* 404.9* (360.6-452.0) 83 23.36 2,863 3.55* 208.3* (149.3-277.8)
Salivary glands 29 20.45 1,480 1.42 57.8 (-7.0-143.3) 14 12.38 1,569 1.13 10.3 (-30.1-70.8)
Oropharynx 550 129.86 10,157 4.24* 413.7* (369.3-460.9) 52 14.54 1,813 3.58* 206.6* (134.0-295.9)
Nasopharynx 13 12.90 1,223 1.01 0.8 (-49.0-76.2) 8 3.33 535 2.41* 87.4* (2.2-232.6)
Hypopharynx 496 129.23 9,334 3.84* 392.9* (347.2-441.8) 27 4.40 577 6.13* 391.8* (232.1-604.9)
Head and neckc 1,981 509.07 38,731 3.89* 380.0* (357.8-403.1) 214 62.40 7,781 3.43* 194.8* (159.2-234.3)
Oesophagus 290 119.03 7,367 2.44* 232.1* (188.1-280.1) 27 11.27 1,244 2.40* 126.5* (52.4-225.2)
Stomach 240 233.16 12,773 1.03 5.4 (-17.7-30.7) 87 83.55 8,739 1.04 3.9 (-15.9-27.2)
Small intestine 32 31.37 1,848 1.02 3.4 (-51.4-74.7) 15 15.39 1,716 0.97 -2.3 (-40.8-54.5)
Colorectum 1,996 1,843.60 97,268 1.08* 15.7* (6.8-24.9) 935 792.53 87,123 1.18* 16.4* (9.6-23.5)
Colon 1,185 1,060.19 55,504 1.12* 22.5* (10.5-35.0) 590 491.42 54,649 1.20* 18.0* (9.5-27.1)
Rectum 810 783.28 41,747 1.03 6.4 (-6.7-20.2) 344 300.88 32,443 1.14* 13.3* (2.4-25.1)
Liver, primary 135 120.50 6,749 1.12 21.5 (-10.8-58.2) 23 13.82 1,709 1.66* 53.7* (4.4-121.1)
Gallbladder and biliary tract 30 38.16 1,950 0.79 -41.9 (-91.9-23.9) 31 24.89 2,463 1.25 24.8 (-15.5-77.6)
Pancreas 33 49.39 2,948 0.67* -55.6* (-90.5--10.3) 25 23.53 2,730 1.06 5.4 (-27.0-49.0)
Nasal cavities and sinuses 50 42.29 2,430 1.18 31.7 (-21.3-97.2) 3 5.90 650 0.51 -44.5 (-81.4-44.1)
Larynx 853 323.02 19,900 2.64* 266.3* (238.0-296.1) 58 16.93 1,995 3.43* 205.9* (135.9-291.0)
Lung, bronchus and trachea 855 599.96 41,161 1.43* 62.0* (48.3-76.4) 96 72.95 9,446 1.32* 24.4* (5.1-46.9)
Pleura 8 13.92 776 0.57 -76.2 (-134.9-23.8) 3 2.45 284 1.22 19.3 (-65.1-222.3)
Bone and cartilages 16 11.53 2,306 1.39 19.4 (-10.4-62.7) 11 8.25 2,087 1.33 13.2 (-13.2-54.8)
Soft tissue 67 55.74 4,965 1.20 22.7 (-7.7-59.1) 39 24.00 3,951 1.62* 38.0* (9.4-74.2)
Melanoma of skin 303 258.43 20,881 1.17* 21.3* (5.5-38.6) 288 208.83 32,126 1.38* 24.6* (14.6-35.6)
Breast 52 45.45 2,282 1.14 28.7 (-29.0-99.6) 2,476 1,885.48 351,434 1.31* 16.8* (14.1-19.6)
Cervix uteri - - - - - - 265 173.92 28,122 1.52* 32.4* (21.4-44.4)
Corpus uteri - - - - - - 511 370.65 41,147 1.38* 34.1* (23.6-45.4)
Ovary and uterine adnexa - - - - - - 189 168.03 22,829 1.12 9.2 (-2.2-21.9)
Vagina and vulva - - - - - - 59 39.51 4,219 1.49* 46.2* (12.8-86.7)
Prostate 3,880 3,500.52 230,582 1.11* 16.5* (11.2-21.8) - - - - - -
Testis 86 59.42 19,448 1.45* 13.7* (4.8-24.1) - - - - - -
Penis 43 42.20 2,303 1.02 3.5 (-48.1-68.3) - - - - - -
Bladder 1,192 729.56 38,002 1.63* 121.7* (104.1-140.0) 99 79.73 7,772 1.24* 24.8* (0.9-52.5)
Kidney 660 471.41 28,385 1.40* 66.4* (49.0-84.9) 198 149.07 17,327 1.33* 28.2* (12.9-45.3)
Melanoma of choroid 23 19.49 1,361 1.18 25.8 (-36.1-110.4) 14 12.84 1,465 1.09 7.9 (-35.4-72.7)
Brain 24 30.03 5,546 0.80 -10.9 (-26.4-10.2) 20 16.84 4,506 1.19 7.0 (-10.3-31.2)
Thyroid gland 88 62.22 7,369 1.41* 35.0* (11.3-62.7) 244 174.12 31,397 1.40* 22.3* (12.8-32.6)
Hodgkin’s disease 69 40.59 8,338 1.70* 34.1* (15.7-56.0) 38 22.16 6,930 1.72* 22.9* (6.8-43.3)
Non-Hodgkin’s lymphoma 448 348.23 26,008 1.29* 38.4* (22.8-55.1) 229 185.26 22,997 1.24* 19.0* (6.5-32.8)
Multiple myeloma 133 125.42 6,934 1.06 10.9 (-20.3-46.4) 73 66.51 6,946 1.10 9.3 (-13.4-36.4)
Leukaemia 377 323.41 22,217 1.17* 24.1* (7.4-42.1) 173 130.86 17,269 1.32* 24.4* (10.0-40.5)
Acute lymphatic leukaemia 4 3.21 3,064 1.25 2.6 (-7.0-23.0) 7 2.91 2,571 2.41 15.9 (-0.4-44.8)
Chronic lymphatic leukaemia 276 219.48 11,261 1.26* 50.2* (22.1-80.9) 123 91.97 9,091 1.34* 34.1* (11.3-60.3)
Acute myeloid leukaemia 21 23.63 2,585 0.89 -10.2 (-41.2-32.8) 23 12.37 2,491 1.86* 42.7* (8.8-88.9)
Chronic myeloid leukaemia 43 47.36 3,291 0.91 -13.3 (-49.4-32.1) 14 16.78 2,234 0.83 -12.4 (-40.9-30.0)
Other sitesd 542 412.95 25,949 1.31* 49.7* (32.5-68.1) 211 186.09 22,084 1.13 11.3 (-1.2-25.1)
All sites d 14,555 10,514.87 689,115 1.38* 58.6* (55.2-62.1) 6,671 5,040.73 751,845 1.32* 21.7* (19.6-23.8)
  1. SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
  2. aExcluding SPC occurring in the same subsite as the first primary cancer.
  3. bNumber of excess cancers per 10,000 person-years at risk.
  4. cHead and neck site includes tongue and lingual tonsil, oral cavity, oropharynx, nasopharynx, hypopharynx and other oral cavity and pharynx.
  5. dExcluding non-melanoma skin cancer.
  6. *P < .05.